Tamil Nadu Leads India with Landmark Free Cancer Vaccination Programme for Girls Aged 1–14

Chennai, October 27, 2025:
In a major public health milestone, Tamil Nadu is set to become the first Indian state to launch a free cancer vaccination programme for girls aged 1 to 14 years. Announced by State Health and Family Welfare Minister Ma. Subramanian on Sunday at the annual breast cancer awareness walkathon ‘Oru Nadai Oru Nambikkai’ (One Step, One Hope), the initiative marks a pioneering step toward preventive oncology in India.​

A First-of-Its-Kind Preventive Campaign

The Tamil Nadu government has allocated ₹38 crore to deliver free cancer-preventive vaccines, expected to focus on protection against the Human Papillomavirus (HPV)—a leading cause of cervical cancer among women. The tender process for vaccine procurement has been completed, and rollout is expected to begin later this year.​

Once implemented, Tamil Nadu will not only be the first state to offer such a comprehensive free vaccination plan but also the first in India to include the broad age range of one to fourteen years. The programme aligns with earlier state budget commitments of ₹36 crore for HPV vaccination for 14-year-old girls announced earlier in 2025.​

Expert Perspectives on Public Health Impact

Dr. T.S. Selvavinayagam, Director of Public Health and Preventive Medicine, emphasized that this campaign could significantly reduce the future burden of cervical cancer—a disease that kills approximately 77,000 Indian women annually, according to World Health Organization data. “Regular vaccination can prevent up to 90% of cervical cancers. Tamil Nadu’s leadership in early inclusion of younger age groups can provide lifelong protection,” said Dr. Selvavinayagam.​

Echoing this, Dr. G.R. Ravindranath, General Secretary of the Doctors Association for Social Equality, welcomed the state’s proactive move, terming it “a transformative model for preventive health policy” that other Indian states should emulate.​

Public health advocates note that early vaccination not only reduces cancer risk but also narrows health inequities by providing free preventive care to economically disadvantaged families.

Context: HPV Vaccination in India

India has been making gradual progress in integrating HPV vaccines into its Universal Immunisation Programme (UIP). Although national rollout has been delayed since the National Technical Advisory Group on Immunisation (NTAGI) first recommended it, Tamil Nadu’s initiative could serve as a model for other states.​

HPV vaccination is globally recognized as one of the most effective ways to prevent cervical and other genital cancers. The vaccine protects against types 16 and 18 of HPV, which are responsible for about 70% of cervical cancer cases worldwide.​

In 2023, India launched its own indigenously developed HPV vaccine, Cervavac, by the Serum Institute of India, priced more affordably to enable large-scale public immunisation. Tamil Nadu’s adoption of a universal free model could accelerate nationwide uptake, particularly in rural and underserved areas.​

Balancing Prevention and Awareness

Minister Subramanian underscored the complementary role of lifestyle and physical fitness in cancer prevention: “Scientific research shows that regular walking and exercise can significantly lower cancer risk. Our goal is to empower citizens with both preventive vaccines and healthy habits”.arched with messages promoting early screening and physical activity. The event also spotlighted the government’s broader focus on women’s health and environmental sustainability, emphasizing Chief Minister M.K. Stalin’s hands-on involvement in public health initiatives.​

The Numbers Behind the Initiative

• Budget allocation: ₹38 crore for 2025–26​

• Target group: Girls aged 1–14 years

• Vaccine: Likely Cervavac (Quadrivalent HPV vaccine)​

• Expected impact: Over 5 million beneficiaries in the initial phase

• Goal: Reduce cervical cancer incidence by up to 90% in vaccinated cohorts

This preventive strategy complements the Union government’s broader plan to integrate the HPV vaccine into India’s national immunization schedule, targeting 90% vaccine coverage among girls under 15 by 2030 under WHO’s cervical cancer elimination roadmap​

Limitations and Next Steps

Public health experts, however, caution that awareness and implementation logistics will be key. Challenges include rural outreach, supply chain management, and the need for parental consent for minors. Health educators stress the importance of continuing cervical cancer screening even after vaccination, as the vaccine does not protect against all HPV strains.

Additionally, the scientific community encourages transparent evaluation of vaccine efficacy in younger age groups under five, as most clinical evidence supports use primarily from ages 9–14. Tamil Nadu officials have yet to confirm whether younger recipients will be included in a phased approach or under special medical guidance.​

National Implications

Tamil Nadu’s bold initiative could catalyse a new chapter in India’s preventive healthcare policy by bridging the gap between research and implementation. Experts describe it as an “operational turning point” that aligns local governance with global cancer elimination strategies.

If successful, the programme could influence the national rollout of free HPV vaccination across all states—mirroring how Tamil Nadu’s maternal health and organ donation models previously became national benchmarks.

As India continues to rise as a global leader in vaccine development and production, such regionally rooted but globally aligned health strategies position the country to make measurable strides toward the World Health Organization’s goal of eliminating cervical cancer as a public health problem by 2030.

Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References​